Hepatic fibrosis therapy - Hawaii Biotech

Drug Profile

Hepatic fibrosis therapy - Hawaii Biotech

Alternative Names: Heptax

Latest Information Update: 16 Mar 2009

Price : $50

At a glance

  • Originator Hawaii Biotech
  • Class Carotenoids
  • Mechanism of Action Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatic fibrosis

Most Recent Events

  • 10 May 2006 Hawaii Biotech has been acquired by Avantogen
  • 20 Jun 2003 Preclinical trials in Hepatic fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top